SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,588 | -22.5% | 1,900 | +11.8% | 0.00% | – |
| Q2 2023 | $35,581 | +17.2% | 1,700 | +18.2% | 0.00% | – |
| Q1 2023 | $30,371 | -16.1% | 1,438 | +0.9% | 0.00% | – |
| Q4 2022 | $36,180 | +16.7% | 1,425 | +11.8% | 0.00% | – |
| Q3 2022 | $31,000 | +29.2% | 1,275 | 0.0% | 0.00% | – |
| Q2 2022 | $24,000 | +9.1% | 1,275 | +2.0% | 0.00% | – |
| Q1 2022 | $22,000 | +340.0% | 1,250 | +400.0% | 0.00% | – |
| Q4 2021 | $5,000 | -77.3% | 250 | -87.5% | 0.00% | – |
| Q1 2020 | $22,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |